MedTrace Logo

Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease

NCT07356050 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2026-01-21

No results posted yet for this study

Summary

The goal of this study is to learn if infants with sickle cell disease (SCD) develop adequate protection after measles vaccines. (not looking at any prolonged duration)

Conditions

Sponsors & Collaborators

  • Thrasher Research Fund

    collaborator OTHER

  • National Institutes of Health (NIH)

    collaborator NIH

  • Children's Hospital Medical Center, Cincinnati

    lead OTHER

Principal Investigators

  • Alexandra Power-Hays, MD · Children's Hospital Medical Center, Cincinnati

Eligibility

Min Age
6 Months
Max Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-13
Primary Completion
2027-12-31
Completion
2028-12-31

Countries

  • United States
  • Ghana
  • Tanzania

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07356050 on ClinicalTrials.gov